NASDAQ:VVUSVIVUS Stock Price, Forecast & News

$1.07

-0.01 (-0.93 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.05

Now: $1.07▼

$1.10

50-Day Range

$1.05

MA: $1.21▼

$1.39

52-Week Range

$0.80

Now: $1.07▼

$4.75

Volume260,800 shs

Average Volume1.36 million shs

Market Capitalization$19.12 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.79

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Beat the Market (BTM) Rank^™

3.0 Analyst's Opinion

Consensus Rating
VIVUS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.75, VIVUS has a potential upside of 63.6% from its current price of $1.07.
Amount of Analyst Coverage
VIVUS has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
VIVUS has received 375 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
VIVUS has received 439 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
VIVUS has received 53.93% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote “Outperform” if you believe VVUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
VIVUS does not currently pay a dividend.
Dividend Growth
VIVUS does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VIVUS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 12.00% of the stock of VIVUS is held by insiders.
Percentage Held by Institutions
Only 7.32% of the stock of VIVUS is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for VIVUS are expected to grow in the coming year, from ($2.27) to ($1.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VIVUS is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VIVUS is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.19 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:VVUS

Previous Symbol

CUSIP92855110

CIK881524

Webwww.vivus.com

Phone650-934-5200

Debt

Debt-to-Equity RatioN/A

Current Ratio0.43

Quick Ratio0.28

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$69.76 million

Price / Sales0.27

Cash FlowN/A

Price / Cash FlowN/A

Book Value($6.50) per share

Price / Book-0.16

Profitability

EPS (Most Recent Fiscal Year)($2.96)

Net Income$-31,500,000.00

Net Margins-39.28%

Return on EquityN/A

Return on Assets-12.18%

Miscellaneous

Employees57

Outstanding Shares17,867,000

Market Cap$19.12 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

How has VIVUS's stock been impacted by COVID-19 (Coronavirus)?

VIVUS's stock was trading at $1.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VVUS stock has increased by 2.9% and is now trading at $1.07. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of VIVUS?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VIVUS in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for VIVUS.

When is VIVUS's next earnings date?

VIVUS is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for VIVUS.

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter. View VIVUS's earnings history.

When did VIVUS's stock split? How did VIVUS's stock split work?

VIVUS shares reverse split before market open on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for VVUS?

1 analysts have issued 1-year target prices for VIVUS's stock. Their forecasts range from $1.75 to $1.75. On average, they anticipate VIVUS's share price to reach $1.75 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price. View analysts' price targets for VIVUS.

Has VIVUS been receiving favorable news coverage?

Headlines about VVUS stock have been trending somewhat positive on Friday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. VIVUS earned a news impact score of 0.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutVIVUS.

Who are some of VIVUS's key competitors?

Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors.

What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Novavax (NVAX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Melinta Therapeutics (MLNT), Inovio Pharmaceuticals (INO), General Electric (GE) and Pfizer (PFE).

Who are VIVUS's key executives?

VIVUS's management team includes the following people:

Mr. John P. Amos, CEO & Director (Age 52)
Mr. Kenneth Suh, Pres (Age 43)
Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)
Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)
Dr. Santosh T. Varghese, Chief Medical Officer (Age 49)

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

Who are VIVUS's major shareholders?

VIVUS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.22%). Company insiders that own VIVUS stock include Eric W Roberts, John P Amos and Mark K Oki. View institutional ownership trends for VIVUS.

Which major investors are selling VIVUS stock?

VVUS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View insider buying and selling activity for VIVUS.

How do I buy shares of VIVUS?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VIVUS's stock price today?

One share of VVUS stock can currently be purchased for approximately $1.07.

How big of a company is VIVUS?

VIVUS has a market capitalization of $19.12 million and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. VIVUS employs 57 workers across the globe.

What is VIVUS's official website?

The official website for VIVUS is www.vivus.com.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff